EBS Insider Buying & Government Contracts (2026)

EBS insider buying and selling over the past year

Insiders at Emergent BioSolutions Inc. only sold stock in the open market over the past year: 3 Form 4 sales totaling $536.2K, against no open-market purchases.

None of the 3 sales were flagged as Rule 10b5-1 plan trades, meaning each one was a discretionary decision at the time of filing. Activity clustered in 2025-11 (2 trades) and 2025-12 (1 trades); the latest filing in this window is dated 2025-12-05. The average open-market sale price was $11.09; the last close of $6.38 is 42.5% below that level, so sellers exited above the current price. The single largest trade was a sale of 21,984 shares worth $263.1K on 2025-12-05. Since the most recent filing the stock has moved -46.4%, from $11.90.

Where EBS trades relative to its one-year range

Emergent BioSolutions Inc. closed at $6.38 on 2026-10-16, inside a one-year range of $4.45 to $13.90. That puts the stock in the middle of its range, at 20.4% of the distance from low to high. Over one year the share price moved -32.1%, and over roughly three months -16.4%. Average daily volume over the last month was about 1,124,227 shares.

Across 137 companies in the same SEC industry group (SIC 28) with a full year of prices in Gemral Edge, the median one-year return was +12.0%. EBS is behind that median and beat 15% of that peer group on this measure.

Members of Congress who traded EBS

STOCK Act disclosures show 1 trades in EBS by 1 members of Congress over five years (0 purchases, 1 sales), most recently on 2024-12-11. The most active traders were Steve Cohen (D-TN), 1 trade.

By party the trades split 1 by Democrats; by chamber, 1 from the House.

Emergent BioSolutions Inc. federal contract exposure

Federal procurement records resolve 1 prime award actions to Emergent BioSolutions Inc., worth $53.98M across 1 agencies. Department of Health and Human Services accounts for 100.0% of that value ($53.98M), so revenue from this channel depends heavily on one buyer.

EBS lobbying disclosures

Emergent BioSolutions Inc. appears in 14 Lobbying Disclosure Act filings between 2018 and 2018, with $1.23M in reported lobbying spend.

Compare EBS with indexed peers from the same industry group

These peers have full Gemral Edge dossiers and the closest one-year price move to EBS:

• NVO one-year return -30.8%
• ZTS one-year return -44.6%
• ABT one-year return -17.8%
• IDXX one-year return -12.1%
• AZN one-year return -1.3%

Sources and method

Every figure above is computed from public filings stored in Gemral Edge, not estimated. Insider figures count only open-market purchases and sales reported on SEC Form 4; option exercises, grants and gifts are excluded because they do not reflect a decision to buy or sell at market prices.

• SEC EDGAR Form 4 (edge_insider_trades, codes P/S open-market only) — as of 2025-12-05
• edge_prices_eod (end-of-day close) — as of 2026-10-16
• House PTR / Senate eFD disclosures (edge_congress_trades) — as of 2024-12-11
• FPDS / USAspending (edge_contracts, tier-1 resolved) — as of 2026-08-18
• Senate LDA filings (edge_lobbying_filings)

EBS data questions

Are EBS insiders buying or selling stock?

Insiders at Emergent BioSolutions Inc. only sold stock in the open market over the past year: 3 Form 4 sales totaling $536.2K, against no open-market purchases.

What is the one-year price range for EBS?

Based on end-of-day closes through 2026-10-16, EBS traded between $4.45 and $13.90, last closing at $6.38.

Has any member of Congress traded EBS stock?

Yes. 1 members disclosed 1 trades in EBS over five years; the most recent disclosed trade date is 2024-12-11.